Condition: Hemorrhage · Urgent Surgery · Invasive Procedure · Sponsor: SFJ Pharmaceuticals, Inc.
This is a multi-center, open-label, prospective single-arm study of reversal of the antiplatelet effects of ticagrelor with bentracimab (PB2452) in patients who present with uncontrolled major or life-threatening bleeding or who require urgent surgery or invasive procedure. At least 200 patients will be enrolled from approximately 200 centers in North America, Europe, and Asia-Pacific regions, including mainland China. Patients with reported use of ticagrelor within the prior 3 days who require urgent ticagrelor reversal will be eligible for enrollment. These populations will be enrolled based on separate inclusion criteria.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| University of Florida Health, Jacksonville | Jacksonville, Florida, United States | — |
| University of Kentucky | Lexington, Kentucky, United States | — |
| Sinai Hospital of Baltimore | Baltimore, Maryland, United States | — |
| Henry Ford Hospital | Detroit, Michigan, United States | — |
| North Kansas City Hospital | North Kansas City, Missouri, United States | — |
| Cox Medical Centers | Springfield, Missouri, United States | — |
| Sanford Medical Center Fargo | Fargo, North Dakota, United States | — |
| Ascension St. John Clinical Research Institute | Tulsa, Oklahoma, United States | — |
| Rhode Island Hospital | Providence, Rhode Island, United States | — |
| Medical University Of Graz | Graz, STY, Austria | — |
| Klinische Abteilung für Innere Medizin 3 Universitätsklinikum St. Pölten | Sankt Pölten, Austria | — |
| Klinik Ottakring 3rd Med Dept, Cardiology and Intensive Care Medicine | Vienna, Austria | — |
+ 56 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04286438